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Abstract
Background: Casein kinase 2 (CK2) is dysregulated in various human cancers and is a promising
target for cancer therapy. To date, there is no small molecular CK2 inhibitor in clinical trial yet.
With the aim to identify novel CK2 inhibitors, we screened a natural product library.
Methods: We adopted cell-based proliferation and CK2 kinase assays to screen CK2 inhibitors
from a natural compound library. Dose-dependent response of CK2 inhibitors in vitro was
determined by a radioisotope kinase assay. Western blot analysis was used to evaluate down
stream Akt phosphorylation and apoptosis. Apoptosis was also evaluated by annexin-V/propidium
iodide (PI) labeling method using flow cytometry. Inhibition effects of CK2 inhibitors on the growth
of cancer and normal cells were evaluated by cell proliferation and viability assays.
Results: Hematein was identified as a novel CK2 inhibitor that is highly selective among a panel of
kinases. It appears to be an ATP non-competitive and partially reversible CK2 inhibitor with an IC50
value of 0.55 μM. In addition, hematein inhibited cancer cell growth partially through down-
regulation of Akt phosphorylation and induced apoptosis in these cells. Furthermore, hematein
exerted stronger inhibition effects on the growth of cancer cells than in normal cells.
Conclusion: In this study, we showed that hematein is a novel selective and cell permeable small
molecule CK2 inhibitor. Hematein showed stronger growth inhibition effects to cancer cells when
compared to normal cells. This compound may represent a promising class of CK2 inhibitors.
Background
CK2 is a serine/threonine protein kinase composed of 2
catalytic subunits (αα, α'α' or αα') and 2 regulatory subu-
nits (β). CK2 is ubiquitously expressed and highly con-
served in cells and plays multiple roles in cellular
processes, including gene expression, protein synthesis,
cell proliferation and apoptosis[1]. So far, CK2 is known
to phosphorylate more than 300 proteins in cells and is
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pathways[2]. For example, CK2 promotes survival by
increasing survivin expression via beta-catenin-Tcf/Lef-
mediated transcription[3]. CK2 also constitutively phos-
phorylates and upregulates Akt/PKB Ser129 in vitro and in
vivo, which may be required for maximal activation of
Akt/PKB[4].
Dysregulation of CK2 in association with other proteins
also increases oncogenic potential of cells[5]. In trans-
genic mouse study, expression of CK2α subunits in lym-
phocyte induces lymphoma, and the coexpression of c-
myc protein results in neonatal leukemia[6]. Overexpres-
sion of CK2α in the mammary gland of transgenic mouse
induces mammary hyperplasia, dysplasia, and eventually
adenocarcinomas[7]. In primary embryo fibroblasts,
coexpression of CK2α' and H-Ras induces transforma-
tion[8]. Overexpression of CK2 has been noted in a vari-
ety of human cancers, including acute myeloid
leukaemia[9], mammary gland[7], prostate[10], lung[11],
head and neck[12], and kidney cancer[13], and also cor-
relates with metastatic potential, undifferentiated histo-
logical type and poor clinical outcome in human cancers.
As a result, CK2 is a potential candidate of targeted ther-
apy for cancers[1]. Although CK2 inhibitors like TBB
(4,5,6,7 tetrabrome benzotriazole)[14] and its deriva-
tives[1,15] have been shown to induce apoptosis in
human cancer cells, more selective CK2 inhibitors are
needed, since to our knowledge there is still not one CK2
small molecule inhibitor in clinical trials for cancer treat-
ment yet.
In this study, we screened for potential CK2 inhibitors
from a natural compound library via cell based prolifera-
tion and kinase assays. Through these assays, hematein
was identified as a novel CK2 inhibitor. We further evalu-
ated the dose dependent inhibition response of hematein
on CK2 kinase activity in vitro and in cancer cells. Effects
of hematein on apoptosis and cell growth were also eval-
uated in cancer and normal cells.
Methods
Cell culture
HeLa (CCL-2), HCT116 (CCL-247), A549 (CCL-185),
A427 (HTB-53), WI-38 (CCL-75) and CCL-211 cell lines
were purchased from American Type Culture Collection
(Manassas, VA). Cells were grown in complete growth
medium (Dulbecco's modified Eagle's medium for HeLa,
A549 and CCL-211; Eagle's Minimum Essential Medium
for WI-38; Roswell Park Memorial Institute's medium for
HCT116 and A427) supplemented with 10% fetal bovine
serum, 10 units/ml penicillin and 10 μg/ml streptomycin
at 37°C and 5% CO2.
Compound library
A natural product library NPL 400 (Timtect Inc., Newark,
DE) was used to screen possible CK2 inhibitors. This
library is composed of 400 highly pure, rationally selected
drug-like small-molecule compounds with molecular
weights ranging from 183 to 832 Da. All compounds were
0.5 mg powder form in individual wells of 96-well plates.
After dissolved with 100 μL of dimethyl sulfoxide
(DMSO), compounds were stored at -20°C with final
concentrations of 5 mg/ml. TBB was purchased from
Sigma-Aldrich Co (St. Louis, MI).
Cell proliferation and viability assay
The CellTiter 96® AQueous One Solution Cell Proliferation
Assay (MTS) (Promega, Madison, WI) was used to evalu-
ate growth of normal and cancer cells after treatment by
different compounds. Exponentially growing cells were
plated in 96-well microtiter plates at 5 × 103 cells/well
with indicated concentrations of compounds. After incu-
bation with indicated amount of compounds for 48
hours, 20 μl of the CellTiter 96® AQueous One Solution Rea-
gent was added directly to culture wells. Absorbance at
490 nm was recorded with a 96-well plate reader after 2
hours incubation.
CellTiter-Glo luminescent cell viability assay (Promega,
Madison, WI) was used to evaluate the cytotoxicity of
hematein. After incubation with indicated amount of
compounds for 48 hours, 100 μl of the CellTiter-Glo rea-
gent was added directly to culture wells. Following proce-
dures recommended by the manufacture, the
luminescence produced by the luciferase-catalyzed reac-
tion of luciferin and ATP was measured using a laminator.
Kinase assays
The CK2 Kinase Assay/Inhibitor Screening Kit (CycLex Co.
Ltd., Japan) was used for further screening of compounds
for their CK2 inhibition effects in vitro according to man-
ufacture's manual[16].
For determination of the dose dependent inhibition
response of hematein, Casein Kinase 2 Assay Kit (Milli-
pore, Bedford, MA) was used according to manufacture's
protocol. Kinase assay was carried out in the presence of
increasing amount of hematein in a final volume of 50 μl
containing 20 mM MOPS (pH 7.2), 25 mM β-glycerol
phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1
mM dithiothreitol, 15 mM Mgcl2, 200 μM for CK2 sub-
strate peptide: RRRDDDSDDD (Millipore, Bedford, MA),
0.05 μg purified active CK2 (Millipore, Bedford, MA) and
[γ-33P]-ATP. After incubation in 30°C for 20 minutes,
assay was stopped by adding of 20 μl 4% trichloroacetic
acid and transferred 25 μl to P81 phosphocellulose
squares. After washing with 0.75% phosphoric acid for 6
times and with acetone for 1 time, phosphocellulosePage 2 of 10
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counting.
Western blot analysis
After treated with indicated concentration of hematein for
48 hours, whole cell protein were extracted from A549
cells with M-PER Mammalian Protein Extraction Reagent
(Pierce, Rockfold, IL) added with Phosphatase Inhibitor
Cocktail Set II (Calbiochem, San Diego, CA) and Com-
plete Protease Inhibitor Cocktails (Roche, Switzerland)
according to manufactures' protocols. The proteins were
used for further CK2 kinase activity assay or western blot
analysis. For western blot analysis, the proteins were sep-
arated on 4–15% gradient sodium dodecyl sulfate (SDS)-
polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore, Billerica, MA). Following primary
antibodies: Akt, PARP (Cell Signaling Technology, Dan-
vers, MA), phospho-Akt S129 (Abcam Inc., Cambridge,
MA) and β-actin (Sigma, St. Louis, MO) were used. After
binding to indicated secondary antibodies, an enhanced
chemiluminescence (ECL) blotting analysis system (GE
Healthcare Life Sciences, Piscataway, NJ) was used for
antigen-antibody detection.
Apoptosis assay
The occurrence of apoptosis was determined by
ApoTarget™ annexin V-FITC kit (BioSource International,
Inc., Camarillo, CA). Briefly, cells were treated with indi-
cated amounts of DMSO or hematein for 48 hours. The
cells were washed with cold PBS and then re-suspended in
binding buffer. The cells were aliquot to 100 μl in a con-
centration of 1 × 106/ml. After adding 5 μl of annexin V-
FITC and 20 μl of PI and incubated in dark for 15 minutes,
the cells were resuspended in 400 μl of binding buffer.
Accuri's C6 Flow Cytometer™ System (Accuri Cytometers,
Ann Arbor, MI) was used for analysis.
Statistical analysis
The data shown represent mean values ± standard error of
deviation (SD). Student's t-test was used for comparing of
cell viability in different treatments. Statistical analysis
was carried out using SPSS (version 10.0, Chicago, IL).
Significance was defined as p < 0.05 with two sided anal-
ysis. The half maximal inhibitory concentration (IC50)
values was determined using GraphPad Prism® log (inhib-
itor) vs. response (variable slope) software (version 5, La
Jolla, CA).
Results
Screening CK2 inhibitors from a natural compound library
First, a cell based MTS cell proliferation assay was used to
evaluate the inhibitory effects of 400 compounds from
NPL compound library on cell proliferation of HCT116
cells. HCT116 cell was selected for initial screening
because previous studies showed that this cell line was
inhibited by CK2 inhibitors[17,18]. After incubation for
48 hours in 96-wells plates, a number of compounds
including 4A3, 4A6 and 4A9, showed inhibition effects on
HCT116 cells proliferation compared to control samples
(DMSO) (Fig 1A).
Second, a non-isotopic CK2 kinase assay was performed
to test the compounds selected from cell based inhibitory
assay for their ability to inhibit CK2 kinase activity in vitro.
Equal concentrations of the indicated compounds were
incubated with purified CK2, and their inhibition effects
were evaluated using 100 μM ATP. Compared to 4A6 and
4A9 compounds, 4A3 compound exerts stronger inhibi-
tion effect on CK2 kinase activity in vitro (Fig. 1B).
Third, the inhibition effects of selected compounds were
further validated by radioisotope CK2 kinase assay at 10
μM ATP and similar results were noted (Fig. 2A). The 4A3
compound is hematein (3, 4, 10, 6a-tetrahydroxy-7, 6a-
dihydroindeno [2, 1-c] chroman-9-one) (Fig 2B).
Hematein inhibits CK2 kinase activity in a selective, dose-
dependent and ATP non-competitive manner in vitro
With the purpose to elucidate the specificity of hematein
to CK2, a kinase panel provided by KinaseProfiler™ service
(Millipore, Dundee, UK) was performed. Among 48
kinases tested in the presence of 10 μM ATP and 10 μM
hematein, hematein exerts > 90% inhibition toward CK2
(Table 1). The IC50 value of hematein is 0.55 μM in the
presence of 10 μM ATP (Fig 3A). However, the IC50 value
did not increase in correspondence to 100 μM ATP (0.27
μM) (Fig 3A). Kinetics study was further performed and
the Linewear-Burk plots showed that hematein is an ATP
non-competitive inhibitor (Fig 3B).
Hematein inhibits CK2 kinase activity in a partially 
reversible manner in vitro
Reversibility test was performed with pre-incubation of
hematein with CK2 in a concentration of 5 μM for 30
minutes. CK2 kinase assay was then performed with the
final concentration of 0.2 μM hematein. The group with
pre-incubation showed roughly 50% kinase activity of the
group without pre-incubation (Fig 3C), indicating that
hematein is a partially reversible inhibitor toward CK2.
Hematein exhibits a mixed inhibition against substrate in 
vitro
The Linewear-Burk plots showed that hematein exhibited
a mixed inhibition against substrate RRRDDDSDDD (Fig
3D). The apparent dissociation constants for hematein
binding were calculated from secondary plots of the
slopes or intercepts obtained from the Linewear-Burk
plots. A secondary plot of the slopes indicated a Kis value
of 0.58 ± 0.09 μM (representing a reversible binding of
hematein to CK2) and a secondary plot of the y-axis inter-Page 3 of 10
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a reversible binding of hematein to CK2-substrate com-
plex).
Hematein inhibits CK2 kinase activity and down stream 
Akt phosphorylation, and induces apoptosis in A549 lung 
cancer cells
Since CK2 kinase showed dose dependent response to
hematein inhibition in vitro, we further evaluated inhibi-
tion effects of hematein on intact cancer cells. First, A549
lung cancer cells were treated with different concentra-
tions of hematein (0 μM to 200 μM), and cellular viability
was measured after 48 hours. Dose dependent response to
inhibition of hematein was noted in A549 cells (Fig 4A).
We next measured CK2 kinase activity in the lysate of
these cells with the same amount of total protein via a
radioisotope CK2 kinase assay described in materials and
methods section. Dose dependent inhibition responses of
CK2 kinase activity were noted in cells treated with 50 μM
and 100 μM of hematein (Fig 4B). Interestingly, Akt
Ser129, which is phosphorylated by CK2 in vitro and in
vivo, also showed significantly decreased phosphorylation
in the cells above (Fig 4C). However, total CK2, total Akt
and β-actin were comparable. Increased cleaved PARP
were also detected in cell lysate treated with 50 μM and
100 μM of hematein (Fig 4C), which indicated increased
caspase dependent apoptosis of cancer cells after
hematein treatment. Compared to DMSO treated cells,
significantly increased apoptotic cells were noted in cells
treated with 50 μM and 100 μM of hematein for 48 hours
(Fig 4D).
Hematein has more inhibition effects to cancer cells 
growth
Finally, we compared inhibition effects of hematein on
normal and cancer cells. Cytotoxicity of hematein against
normal and cancer cells was measured using the CellTiter-
Glo luminescent cell viability assay (Promega, Madison,
WI) to overcome the interference of hematein to MTS
assay. Indicated cells were treated with different concen-
trations of hematein for 48 hours, and cell viability was
measured by the CellTiter-Glo luminescent cell viability
assay. From dose response curve, IC50 values were calcu-
lated in CCL-211 (118.3 ± 15.7 μM) and WI-38 (150.3 ±
26 μM) normal cells than in Hela (57.7 ± 3.4 μM), A549
(90.0 ± 3.8 μM), A427 (62.9 ± 1.7 μM) and HCT116
(100.4 ± 7.3 μM) cancer cells (Fig 5A). Significantly higher
IC50 values (p < 0.05) were noted in CCL-211 cells com-
Inhibition effects of compounds plate 4 on HCT116 cells proliferation and in-vitro inhibition effects of selected compounds on CK2 kinas  activityFigure 1
Inhibition effects of compounds plate 4 on HCT116 cells proliferation and in-vitro inhibition effects of selected 
compounds on CK2 kinase activity. A. After incubation with HCT116 cells for 48 hours, compounds 4A3 (hematein), 4A6 
and 4A9 showed inhibitory effects on cell proliferation compared to the control sample (*4A1, DMSO). The longitudinal values 
revealed the absorbance at 490 nm recorded using an ELISA plate reader after addition of Cell Titer 96 AQueous One Solu-
tion Reagent to each well for 2 hours. Data represents the average of duplicate wells and bars indicate SD. Compound concen-
tration: 4A3: 16.6 μM; 4A6: 23.1 μM; 4A9: 14.2 μM. B. Equal amounts (100 μM) of compounds were incubated with purified 
CK2, and CK2 activity was measured by Cyclex CK2 Assay/Inhibitor Screening Kit using 100 μM ATP. Ck2 kinase activity is 
represented as relative CK2 activity to controls (DMSO). Data represents the average of duplicate wells and bars indicate 
SD.4A3: hematein. Other negative results are not shown.Page 4 of 10
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compared to Hela, A549, A427 and HCT116 cells. As the
result, hematein has stronger inhibition effects towards
cancer cells. We also took the advantage of the staining
property of hematein to observe whether normal cells
uptake hematein and hematein nuclear staining was
noted in cells after treated with 50 μM hematein for 48
hours (Fig 5B).
Discussion
Cell-based screening of compound libraries have been
adopted to discover possible anti-cancer small molecules
in myeloma, breast cancer and colon cancer cells [19-21].
In this study, we also combined a cell based assay with
kinase assay for screening CK2 inhibitors from a natural
compound library. Through these assays, we identified
and validated hematein as a novel CK2 kinase inhibitor.
Hematein is a natural compound isolated from Caes-
alpinia sappan, and has been used as a herbal drug in ori-
ental medicine as both an analgesic and an anti-
inflammatory agent[16] and also used in staining [22].
Our study for the first time discovered that hematein as a
CK2 kinase inhibitor both in vitro and in cancer cells. The
Validation of inhibition effects of selected compounds on CK2 kinase activity and structures of compoundsFigure 2
Validation of inhibition effects of selected compounds on CK2 kinase activity and structures of compounds. A. 
Inhibition effects of selected compounds on CK2 kinase activity was validated by radioisotope kinase assay at a concentration 
of 10 μM compound using 10 μM ATP. TBB is the positive control. Ck2 kinase activity is represented as relative CK2 activity 
to controls (DMSO). Data represents the average of duplicate experiments and bars indicate SD.4A3: hematein. B. Structure of 
compounds: 4A3 (hematein): 3, 4, 10, 6a-tetrahydroxy-7, 6a-dihydroindeno [2, 1-c] chroman-9-one MW 300.26, CAS No. 
15489-90-4; 4A6: 5-methoxyfurano [3,2-g]chromen-2-one; 4A9: 4-hydroxy-3-{2- [8-hydroxy-7-(hydroxymethyl)-1,7-dimethyl-
3-methylenebicyclo[4. 4.0]dec-2-yl]ethylidene}-4,5-dihydrofuran-2-one.Page 5 of 10
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activity is comparable to other CK2 inhibitors ever discov-
ered, such as [5-oxo-5, 6-dihydroindolo-(1, 2-a) quinazo-
lin-7-yl] acetic acid (IQA) (0.39 μM), TBB (0.50 μM) [1],
1, 3, 8-trihydroxyanthraquinone (emodin) (0.89 μM) and
2-Dimethylamino-4,5,6,7-tetrabromo-1 H-benzimida-
zole (DMAT) (0.15 μM)[15]. Kinetic assays in our study
also showed that hematein is an ATP non-competitive
inhibitor toward CK2. Non-competitive inhibitor of ATP
has been shown to be less toxic, and has the advantage of
no need to compete with high intracellular ATP concen-
tration. Our data implies that hematein may inhibit CK2
through an allosteric mechanism. Recently, Raaf et al
reported an allosteric binding site for the small molecule
CK2 inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenz-
imidazole (DRB)[23]. More studies are needed to under-
stand thoroughly the nature and mechanisms of the CK2
inhibition by hematein.
We showed that hematein also induced apoptosis of can-
cer cells. Earlier studies indicate that CK2 plays a key role
in suppression of apoptosis. Overexpression of CK2 in
cancer cells protects cells from etoposide- and diethyl-
stilbestrol-induced apoptosis[24], results in suppression
of apoptosis mediated by tumor necrotic factoralpha
(TNF-α), TRAIL and Fas L, and augments apoptosis in
cells responsive to these ligands[16]. It has been noted
that treatment of a variety of cancer cells with cell perme-
able CK2 inhibitors such as TBB, IQA and DMAT results in
activation of caspases and then aopotosis[1,14,25].
Hematein is reported to reduce the TNF-α-induced expres-
sion of vascular cell adhesion molecule-1 (VCAM-1) and
monocyte chemotactic protein-1 (MCP-1)[16,26], and to
decrease reactive oxygen species generation and nuclear
factor-kappa B (NF-κB) activation [27]. In our study,
hematein inhibited Akt/PKB Ser129 phosphorylation in
cancer cells. Akt/PKB Ser129 plays a role in constitutive
activation of Akt/PKB pathway by CK2[4], which pro-
motes cell survival through activation of anti-apoptotic
pathways such as NF-κB pathway and suppression of cas-
pases activity[28]. Thus, hematein induces apoptosis in
cancer cells at least partially through inhibition of Akt/
PKB pathway by down regulation of CK2 kinase and then
decreased phosphorylation of Akt/PKB Ser129.
Table 1: Specificity spectrum of hematein.
Protein kinase Kinase activity (%) Protein kinase Kinase activity (%)
Abl 76 Lyn 111
CDK1 95 MAPK1 87
CDK2 113 MAPK2 74
CDK3 55 MKK6 99
CDK5 84 MSK1 91
CDK7 106 MSK2 72
CHK1 65 mTOR 103
CK1 82 p70S6K 61
CK2 0 PDGFRα 103
cKit 83 PDK1 96
c-RAF 102 Pim-1 58
cSRC 94 Pim-2 81
DRAK1 51 Pim-3 50
DYRK2 91 PKA 95
EGFR 31 PKBα 92
Flt1 31 PKCα 36
Flt3 83 PKD2 58
GCK 94 PRAK 65
GSK3β 147 ROCK-II 75
HIPK1 94 SAPK2a 121
HIPK2 76 SAPK3 99
HIPK3 96 SAPK4 112
KDR 62 SGK 92
Lck 113 Syk 136
Residual activity is determined in the presence of 10 μM hematein under 10 μM ATP and expressed as a percentage of the control without 
inhibitor. Residual activities ≤ 10% are shown in bold. CDK, cyclin-dependent kinase; CHK, checkpoint kinase; CK, casein kinase; SRC, sarcoma 
kinase; DRAK, DAP kinase-related apoptosis-inducing protein kinase; DYRK, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase; EGFR, 
epidermal growth factor receptor; Flt, fms-related tyrosine kinase; GCK, gluokinase; GSK, glycogen synthase kinase; HIPK, homeodomain 
interacting protein kinase; KDR, kinase insert domain receptor; Lck, lymphocyte cell-specific protein-tyrosine kinase; MAPK, mitogen-activated 
protein kinase; MKK, mitogen-activated kinase; MSK, mitogen- and stress-activated protein kinase; mTOR, mammalian target of rapamyin; p70S6K, 
p70 S6 kinase; PDGFR, platelet-derived growth factor receptor; PDK, 3'-phosphoinositide-dependent kinase; PKA, protein kinase A; PKB, protein 
kinase B; PKC, protein kinase C; PKD, protein kinase D; PRAK, p38-regulated activated kinase; ROCK, Rho-dependent protein kinase; SRPK, 
serine-arginine protein kinase; SGK, serum and glucocorticoid-inducible kinase.Page 6 of 10
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Dose- dependent response, kinetics analysis and reversibility assay of CK2 inhibition by hemateinFigure 3 (see previous pag )
Dose- dependent response, kinetics analysis and reversibility assay of CK2 inhibition by hematein. A. CK2 was 
assayed with specific peptide described in the material and method section with the increasing concentrations of the inhibitor 
using 10 μM and 100 μM ATP. B. The Linewear-Burk plots illustrate the non-competitive inhibition of hematein relative to ATP 
toward CK2. Substrate concentration was fixed at 200 μM. CK2 activity was determined in 0 μM, 1 μ and 4 μM hematein. The 
data represents means of duplicate experiments with SE never exceeding 10%. C. Reversibility assay of hematein. Hematein 
was pre-incubated with CK2 at a concentration of 5 μM for 30 minutes and then kinase assay was performed under 0.2 μM 
final concentration of hematein. Ck2 kinase activity is represented as relative CK2 activity to controls (DMSO). Data points 
represent the average of duplicate experiments and bars indicate SD. D. The Linewear-Burk plots illustrate the mixed inhibi-
tion of hematein relative to substrate toward CK2. ATP concentration was fixed at 10 μM. CK2 activity was determined in 0 
μM, 1 μM and 4 μM hematein. The data represents means of duplicate experiments with SE never exceeding 10%.
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Inhibition effects of hematein on cellular viability and kinase activity in cancer cellsFigure 4
Inhibition effects of hematein on cellular viability and kinase activity in cancer cells. A. A549 cells were treated 
with serial dilutions of hematein (0 to 200 μM) and cellular viability (normalized to DMSO control) was measured after 48 
hours. Data points represent the average of duplicate wells in triplet experiments and bars indicate SD. B. A549 cells were 
treated with DMSO (control), 50 μM and 100 μM of hematein for 48 hours. Upper western blot panel showed total amount of 
CK2 used for CK2 kinase assay, and lower table showed relative CK2 kinase activity (normalized to DMSO control) under dif-
ferent hematein concentrations. Data points represent the average of duplicate experiments and bars indicate SD. C. Phospho-
rylated Akt (Ser 129), total Akt, and PARP were measured by western blot analysis. β-Actin was used as internal loading 
control. Bands quantization of phosphorylated Akt (Ser 129) was obtained by an analysis with Quantity One 1-D analysis soft-
ware. Values are reported below each band and normalized to DMSO control. "*" denotes p < 0.05 when compared with con-
trol values in triplet experiments. D. The fraction of cells undergoing apoptotic cell death was detected using annexin V FITC 
and PI stain. Data points represent the average of triplet independent experiments and bars indicate SD. "*" denotes p < 0.05 
when compared with the control values.
BMC Cancer 2009, 9:135 http://www.biomedcentral.com/1471-2407/9/135Compared to TBB, hematein has similar on CK2 kinase
inhibition in vitro and in cancer cells. However, TBB exerts
inhibition effects on both normal and cancer cells[29]. In
the contrary, hematein exerts relatively stronger inhibi-
tion effects on cancer cells than in normal cells in our
study. Since hematein exerts different inhibition effects on
the growth of cancer and normal cells, which is probably
due to its ATP non-competitive inhibition mechanism
and high selectivity. Thus, hematein may provide a clue
for design of new class of CK2 inhibitors.
Conclusion
In this study, we identified hematein as a novel CK2 small
molecule inhibitor from a natural compound library and
showed that hematein is a selective and cell permeable
CK2 inhibitor. Hematein showed stronger growth inhibi-
tion effects to cancer cells when compared to normal cells.
This compound may represent a promising class of CK2
inhibitors.
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Inhibition effects of hematein on cellular growth in normal and cancer cellsFigure 5
Inhibition effects of hematein on cellular growth in normal and cancer cells. A. Normal (WI-38, CCL-211) and can-
cer (Hela, A549 and A427, HCT116) cells were cultured in the absence and in increasing concentrations of hematein (10 μM 
to 100 μM) as indicated. Cellular viability (normalized to DMSO control) was measured after 48 hours using CellTiter-Glo® 
Luminescent cell viability assay. Data points represent the average of IC50 value of hematein in triplet experiments and bars 
indicate SD. "*" denotes p < 0.05 when compared with IC50 values of CCL-211 cells and "†" denotes p < 0.05 when compared 
with IC50 values of WI-38 cells. B. CCL-211 cells were incubated in the absence and presence of 50 μM hematein for 48 hours. 
Block arrows indicate staining of the nucleus after hematein incubation. Original magnification: × 100.Page 9 of 10
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